Endocrinology, Vol 116, 170-179, Copyright © 1985 by Endocrine Society

ARTICLES

Glucocorticoid regulation of alkaline phosphatase in the osteoblastic osteosarcoma cell line ROS 17/2.8

RJ Majeska, BC Nair and GA Rodan

Dexamethasone increased alkaline phosphatase levels up to 7-fold in the osteoblast-like rat osteosarcoma cell line ROS 17/2.8. This effect was associated with reduced cell growth and took place over several days in culture. The increase in enzyme activity was dose dependent, (half- maximum near 1 nM, with a hormone specificity suggesting glucocorticoid receptor mediation). Dexamethasone also increased enzyme activity in ROS 2/3 cells, but not in two nonosteoblastic osteosarcoma cell lines, indicating that among these cell lines, the effect is specific for osteoblast-like cells. Moreover, enzyme activity in both control and dexamethasone-treated cells correlated directly with levels of radioimmunoassayable bone-type isoenzyme. Increases in alkaline phosphatase activity in response to dexamethasone were detectable after about 5 h and were inhibited by both actinomycin D and cycloheximide. Thus glucocorticoids appear to increase de novo enzyme synthesis in ROS 17/2.8 cells. Finally, the cAMP-elevating agents PTH, isoproterenol, and 8-bromo-cAMP, which were previously shown to reduce alkaline phosphatase activity in osteoblast-like cells, antagonized the effects of dexamethasone. Moreover, in the presence of dexamethasone, lower concentrations of these agents were required for inhibitory effects on alkaline phosphatase.

This article has been cited by other articles:

				R. A Zirngibl, J. S M Chan, and J. E Aubin Estrogen receptor-related receptor {alpha} (ERR{alpha}) regulates osteopontin expression through a non-canonical ERR{alpha} response element in a cell context-dependent manner J. Mol. Endocrinol., February 1, 2008; 40(2): 61 - 73. [Abstract] [Full Text] [PDF]

				C. S. Shin, M. J. Jeon, J.-Y. Yang, S.-J. Her, D. Kim, S. W. Kim, and S. Y. Kim CCAAT/enhancer-binding protein {delta} activates the Runx2-mediated transcription of mouse osteocalcin II promoter. J. Mol. Endocrinol., June 1, 2006; 36(3): 531 - 546. [Abstract] [Full Text] [PDF]

				M. J. Jeon, J. A. Kim, S. H. Kwon, S. W. Kim, K. S. Park, S.-W. Park, S. Y. Kim, and C. S. Shin Activation of Peroxisome Proliferator-activated Receptor-{gamma} Inhibits the Runx2-mediated Transcription of Osteocalcin in Osteoblasts J. Biol. Chem., June 20, 2003; 278(26): 23270 - 23277. [Abstract] [Full Text] [PDF]

				K. Mori, A. Shioi, S. Jono, Y. Nishizawa, and H. Morii Dexamethasone Enhances In Vitro Vascular Calcification by Promoting Osteoblastic Differentiation of Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., September 1, 1999; 19(9): 2112 - 2118. [Abstract] [Full Text] [PDF]

				F. Lecanda, D. A. Towler, K. Ziambaras, S.-L. Cheng, M. Koval, T. H. Steinberg, and R. Civitelli Gap Junctional Communication Modulates Gene Expression in Osteoblastic Cells Mol. Biol. Cell, August 1, 1998; 9(8): 2249 - 2258. [Abstract] [Full Text]

				B. Sukhu, B. Rotenberg, C. Binkert, H. Kohno R. ZOHAR, C. A. G. McCulloch, and H. C. Tenenbaum Tamoxifen Attenuates Glucocorticoid Actions on Bone Formation in Vitro Endocrinology, August 1, 1997; 138(8): 3269 - 3275. [Abstract] [Full Text] [PDF]

				A. Hollnagel, D. Schroder, and G. Gross Domain-specific Gene Activation by Parathyroid Hormone in Osteoblastic ROS17/2.8 Cells J. Biol. Chem., September 6, 1996; 271(36): 21870 - 21877. [Abstract] [Full Text] [PDF]

				M. A. V. Molen, C. T. Rubin, K. J. McLeod, L. K. McCauley, and H. J. Donahue Gap Junctional Intercellular Communication Contributes to Hormonal Responsiveness in Osteoblastic Networks J. Biol. Chem., May 24, 1996; 271(21): 12165 - 12171. [Abstract] [Full Text] [PDF]